The Society for Mucosal Immunology (SMI), the preeminent international community of researchers working together to advance the field of mucosal immunology and improve health worldwide, and Elsevier, a global leader in research publishing and information analytics, are delighted to announce a new partnership to publish SMI’s official journal, Mucosal Immunology. The journal will transition to gold open access, making articles immediately and permanently available for everyone to read, download, copy and distribute. It will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2023.
With a mission to support research and education, and to foster communication and collaboration in the field of mucosal immunology, this decision to partner with Elsevier and move to gold open access furthers the Society’s continued work to connect the mucosal immunology community both as scientists – but also with access to research in our efforts to improve health worldwide through driving innovation in the field. SMI is excited to continue offering strong membership benefits connected to our journal with this change to gold open access, with a 20% discount on open access fees extended to all SMI members.
SMI President Michael McGuckin, PhD, said: “We welcome Elsevier as our new publisher and look forward to taking advantage of its publishing expertise and commitment to open science as we continue our journey to increase the visibility and influence of Mucosal Immunology together. It is clear from our early interactions with Elsevier staff and leadership that this will be a partnership in the truest sense of the word and enable us to build upon the journal’s high standards and further enhance its global prominence.”
Since 1990, mucosal immunology has expanded from what many considered a niche discipline to one of the hottest areas in immunobiology today, underpinned by interactions with the microbiome and nervous system that have profound implications for health and disease. The journal fosters cross-fertilization between scientists, clinical researchers and industry professionals across a broad spectrum of specialties working on pathways of immunity and inflammation at barrier surfaces. They rely on Mucosal Immunology for the very latest robust, cutting-edge original research and reviews in basic, translational and clinical science.
The journal has earned a strong reputation for publishing papers based on the quality of the science, its rapid and rigorous peer review, and its contributions to advancing the field. This is demonstrated by its impressive 2021 Journal Impact Factor of 8.701* and a steadily increasing online and social media community.
Mucosal Immunology’s eminent international editorial board under the continued leadership of Editor-in-Chief Ben Marsland, PhD, ensures that this high quality, peer-reviewed journal will continue to be an authoritative resource for the community it serves.
“The editorial board and I are tremendously excited for the opportunity to partner with Elsevier to publish Mucosal Immunology,” said Professor Marsland. “I have every confidence that support from the Elsevier team will foster even greater success in our ongoing efforts to publish novel, transformative, and clinically relevant science. On behalf of Mucosal Immunology’s editors, editorial staff, reviewers, and authors, I want to welcome our new partner. Elsevier is firmly committed to the continuity of the journal’s rigorous editorial process and accessibility of content, and further solidifying Mucosal Immunology’s reputation."
“We are delighted that SMI has selected Elsevier as its publishing partner. By combining their expertise with Elsevier’s industry-leading resources for authors, editors, peer reviewers and readers, we will ensure the best possible support for SMI’s mission and community. By working together, we can achieve a more inclusive, collaborative and transparent world of research,” stated Louise Curtis, Senior Vice President, Life Sciences & Social Sciences, at Elsevier.
“Mucosal Immunology is a great asset to the Elsevier immunology journal portfolio, and we look forward to helping the society and their journal navigate a successful transition to full open access status,” added Jenny Henzen, Elsevier’s Publisher for Immunology.
*Journal Citation Reports, Clarivate, 2022
Notes for editors
About Mucosal Immunology
Mucosal Immunology is the official publication of the Society for Mucosal Immunology (SMI). It aims to provide a forum for both basic and clinical scientists to discuss all aspects of immunity and inflammation involving barrier tissues. The journal reflects the interests of scientists studying gastrointestinal, pulmonary, nasopharyngeal, oral, ocular, genitourinary and skin immunology through the publication of original research articles, scholarly reviews, and timely commentaries. Publication of basic, translational, and clinical studies are given equal consideration. In addition,
aims to provide a primary method of communication for the SMI governing board and its members through the publication of society news, announcements of planned meetings and conferences, discussions of policy concerns, and advertisements for job and training opportunities. Beginning January 2023, all articles will be published as gold open access through CC BY licenses.
About the Editor-in-Chief
Ben Marsland completed his PhD in Immunology at Otago University and the Malaghan Institute of Medical Research, Wellington, New Zealand. He then spent 14 years in Switzerland, first at the ETH Zürich and then as a Cloetta Medical Research Fellow at the University Hospital of Lausanne (CHUV). During that period, he received the ETH Latsis Prize, the Leenaards Prize and the ERS COPD Research Award. Since 2018, Ben is a
veski innovation fellow), NHMRC Senior Research Fellow and Professor in the Department of Immunology and Pathology within the Central Clinical School at Monash University. He also maintains a visiting professorship at the University of Lausanne and CHUV. The focus of Ben’s lab revolves around the microbiome in the gut, lung and skin and how it influences asthma, respiratory viral infections and lung fibrosis.
About Elsevier and society partnerships
Elsevier has long-standing partnerships with over 600 learned societies worldwide, helping them to realize their missions and inspire and support their communities. We pride ourselves on consistently delivering outstanding publishing outcomes through strategic insight, reliable finances, global dissemination, embracing open science and open access, and championing the needs of the communities we jointly serve. www.elsevier.com/societies
In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.
Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect
, ClinicalKey and Sherpath support strategic research management
, R&D performance
, clinical decision support, and health education
. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell
; our over 43,000 eBook titles; and our iconic reference works, such as
Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board
, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX
, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com